Exclusive news, analysis, and commentary on Big Pharma, hospitals, and biotech.
The pandemic saw a flurry of investment in biotech startups but the past three years have seen shrinking investments in the sector.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The US is the WHO’s biggest donor, chipping in roughly 18% of the organization’s $2 billion to $3 billion annual budget.
Some 8,000 industry movers and shakers are expected today for the annual JPMorgan Healthcare Conference, or simply JPM.
Novo Nordisk on Wednesday announced an expanded deal with healthtech firm Valo Health to use AI to fuel drug discovery.
Traditionally, New Year’s resolutions to lose weight involve getting to the gym more. In a post-GLP-1 world, that’s looking less necessary.
One ring to rule them all… at least, Oura hopes so. On Thursday, it announced a new $200 million funding round.
By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals’ dominance in the GLP-1 space.
Sometimes, markets don’t need breathless buzzwords to get excited. Sometimes, “marginally encouraging” will do. Ask Pfizer shareholders.
Novartis is banking on the startup’s promising treatment candidates for neuromuscular diseases, many of which are genetic in nature.
A treasure trove of genetic data may hold the key to a revolution in drug development, but it offers no clues for building a business.
Dissapointing results for two mid-stage trials strikes a blow in Abbvie’s expensive pipeline-via-M&A strategy.
Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the moment, Eli Lilly.
It’s just another earnings week in the life of pharmaceutical CEOs, with blockbuster expectations running up against cruel reality.
Modifi Biosciences announced that it has been acquired by global pharmaceutical giant Merck, with a $30 million down payment.
Walmart announced on Tuesday that it’s introducing a new same-day delivery service for prescription medication.
A new study suggests increasingly popular GLP-1 drugs could help cut opioid and alcohol abuse nearly in half.